Publications in collaboration with researchers from Hospital Morales Meseguer (147)

2022

  1. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

    Thrombosis and Haemostasis, Vol. 122, Núm. 10, pp. 1625-1652

  2. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 11, pp. 1844-1871

  3. Current trends on antithrombotic therapy

    REC: CardioClinics

  4. Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?

    Revista Espanola de Cardiologia, Vol. 75, Núm. 9, pp. 705-706

  5. Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system

    Frontiers in Cardiovascular Medicine

  6. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 282-289

  7. Outcome of patients with acute heart failure secondary to acute myocardial infarction treated with noninvasive mechanical ventilation

    Revista Espanola de Cardiologia, Vol. 75, Núm. 1, pp. 50-59

  8. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  9. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46